METHODS OF ADMINISTERING ANTI-71).$17,%2',
Application 1096/MUMNP/2003 published 2006-07-28, filed 2003-11-27
Methods of treatingNIL disorders in which TNF alpha activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis IDFWRUDOSKD K71). DUHGLVFORVHG7KHDQWLERG\PD\EHDGPLnistered with or without methotrexate. These antibodies have KLJKDIILQLW\IRUK71). HJ.d = 10-80RUOHVV DVORZRIIUDWHIRUK71).GLVVRFLDWLRQ HJ.off = 10-3 sec-1or less) and QHXWUDOL]HK71).DFWLYLW\in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention. Drawing: 6 Sheets Total Pages: 55 Fig. NIL
Applicant
ABBOTT BIOTECHNOLOGY LTD.
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11, BERMUDA, GREAT BRITAIN
Inventor
1. KAMPENI JOACHIM 2. WEISS ROBERTA 3. FISCHKOFF STEVEN A.
International Info
Classification: A61K
Publication Number: WO 02/100330
Application Date: 2002-06-05
Priority Information
60/296,961 U.S.A. 2001-06-08